DarioHealth Announces Two New Contracts within the Employer Market
Dario's new employer clients include a contract for its full suite of digital therapeutic solutions
Jan 6, 2022
NEW YORK, Jan. 6, 2022 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO), a leader in the global digital therapeutics (DTx) market, announced two new contracts today to provide its highly personalized digital therapeutics beginning in the first quarter of 2022.
The new clients include a large Northeast regional employer in the finance industry set to deploy Dario's full suite of solutions, and a Northeast regional employer in the food industry contracted to deploy Dario's digital therapeutic solution for diabetes.
Dario's digital therapeutics platform provides highly personalized support for people living with diabetes, pre-diabetes, hypertension, weight management, musculoskeletal and behavioral health needs through a combination of innovative technologies, digital tools and expert human support. Full integration across a single AI-driven behavior change engine addresses the underlying health behaviors using intelligence gathered from billions of data points collected over ten years of consumer engagement to create a holistic, seamless member experience proven to deliver sustainable engagement and results.
"Dario captured significant momentum in the employer market during the final quarter of 2021, and we are pleased to start the year with additional agreements that will contribute to 2022 revenue. The addition of another client for our full suite of solutions is particularly exciting, as we believe more employers are finding value in our integrated multi-condition suite in comparison to individual point solutions, and we look forward to expanding our clients across the full suite this year," said Rick Anderson, President and General Manager North America.
About DarioHealth Corp.
DarioHealth Corp. (Nasdaq: DRIO) is a leading global digital therapeutics company revolutionizing how people with chronic conditions manage their health. DarioHealth offers one of the most comprehensive digital therapeutics solutions on the market - covering multiple chronic conditions including diabetes, hypertension, weight management, musculoskeletal and behavioral health within one integrated technology platform.
Dario's next-generation, AI-powered, digital therapeutic platform supports more than just an individual's disease. Dario provides adaptive, personalized experiences that drive behavior change through evidence-based interventions, intuitive, clinically proven digital tools, high-quality software, and coaching to help individuals improve health and sustain meaningful outcomes.
Dario's unique user-centric approach to product design and engagement creates an unparalleled experience that is highly rated by users and delivers sustainable results.
The company's cross-functional team operates at the intersection of life sciences, behavioral science, and software technology and utilizes a performance-based approach to improve its users' health.
On the path to better health, Dario makes the right thing to do the easy thing to do. To learn more about DarioHealth and its digital health solutions, or for more information, visit http://dariohealth.com.
Cautionary Note Regarding Forward-Looking Statements
This news release and the statements of representatives and partners of DarioHealth Corp. related thereto contain or may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements that are not statements of historical fact may be deemed to be forward-looking statements. For example, the Company is using forward-looking statements in this press release when it discusses the expected timing of the new clients providing the Dario platform and solution to its users, that the agreements will contribute to 2022 revenue and the belief that employers are finding value in its integrated multi-condition suite in comparison to individual point solutions and that it looks forward to expanding its clients across the full suite this year. Without limiting the generality of the foregoing, words such as "plan," "project," "potential," "seek," "may," "will," "expect," "believe," "anticipate," "intend," "could," "estimate" or "continue" are intended to identify forward-looking statements. Readers are cautioned that certain important factors may affect the Company's actual results and could cause such results to differ materially from any forward-looking statements that may be made in this news release. Factors that may affect the Company's results include, but are not limited to, regulatory approvals, product demand, market acceptance, impact of competitive products and prices, product development, commercialization or technological difficulties, the success or failure of negotiations and trade, legal, social and economic risks, and the risks associated with the adequacy of existing cash resources. Additional factors that could cause or contribute to differences between the Company's actual results and forward-looking statements include, but are not limited to, those risks discussed in the Company's filings with the U.S. Securities and Exchange Commission. Readers are cautioned that actual results (including, without limitation, the timing for and results of the Company's commercial and regulatory plans for Dario™ as described herein) may differ significantly from those set forth in the forward-looking statements. The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.
DarioHealth Corporate Contact
SOURCE DarioHealth Corp.